按类型、治疗方法、阶段、给药途径和地区分類的老龄化黄斑部病变治疗市场规模、份额和增长分析 - 行业预测（2026-2033 年）

全球老龄化黄斑部病变治疗市场规模预计在 2024 年达到 181.2 亿美元，从 2025 年的 196.6 亿美元增长到 2033 年的 377.6 亿美元，在预测期（2026-2033 年）内复合年增长率为 8.5%。

由于老龄化黄斑部病变黄斑部病变（AMD）盛行率不断上升以及人口老化，全球老龄化治疗市场正经历快速成长。该领域致力于透过满足未被满足的需求来改善患者的生活品质。关键的成长要素包括抗血管内皮生长因子（抗VEGF）疗法和缓释性药物递送系统等治疗技术的进步，这些进步显着改善了患者的治疗效果。此外，人们对早期检测重要性的认识不断提高，也推动了对有效治疗方法的需求。然而，高昂的治疗成本和监管方面的挑战依然存在。值得关注的趋势包括：联合治疗的兴起，这些疗法能够有效靶向多种疾病路径；以及新型基因治疗方法的出现。在人工智慧和机器学习在个人化医疗领域的进步支持下，尤其是在亚太和拉丁美洲等地区，存在着巨大的未开发机会。

推动全球老龄化黄斑部病变治疗市场发展的因素

老龄化黄斑部病变（AMD）治疗市场受到人口老化加剧的显着影响。由于该疾病主要影响50岁及以上人口，随着全球老年人口的增长， 黄斑部病变老龄化将上升。全球人口趋势显示黄斑部病变人口将显着增长，因此对有效治疗方法的需求预计将大幅增长。这种转变凸显了开发创新治疗方案以应对老龄化挑战的必要性，从而推动市场成长，并促进针对该族群的治疗方法和医疗保健解决方案的进步。

限制全球老龄化黄斑部病变治疗市场的因素

由于严格的监管要求和漫长的新治疗方法核准流程，全球老龄化黄斑部病变治疗市场面临严峻挑战。创新疗法的研发需要大规模的临床试验、全面的安全性评估和详尽的监管申报，所有这些都耗费了大量的时间和金钱。这种复杂的监管环境可能会阻碍一些製药公司在该领域进行研发，从而限制新疗法的上市。这可能导致新疗法的研发进展缓慢，并阻碍患者获得先进的黄斑部病变治疗方法。

全球老龄化黄斑部病变治疗市场趋势

全球老龄化黄斑部病变)治疗市场正日益受到远端医疗和远端监测技术的影响。这些技术正在改变患者照护模式，实现对视力和疾病进展的远端评估，从而最大限度地减少频繁的面对面就诊。透过利用居家视力检查和智慧型手机影像设备，医疗服务提供者可以确保及时介入和更好地管理疾病，从而提高患者的便利性并优化医疗成本。这种向数位化解决方案的转变标誌着医疗实践的演进，并凸显了老龄化治疗领域致力于在黄斑部病变治疗通讯协定的同时改善患者预后的决心。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术进步

全球老龄化黄斑部病变治疗市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 干性老龄化黄斑部病变
• 湿性老龄化黄斑部病变
• 其他的

全球老龄化黄斑部病变治疗市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 抗血管内皮生长因子
• 其他的

全球老龄化黄斑部病变治疗市场规模（按阶段和复合年增长率划分）（2026-2033 年）

• 早期老龄化黄斑部病变（AMD）
• 过渡时期老龄化黄斑部病变（AMD）
• 晚期老龄化黄斑部病变（AMD）

全球老龄化黄斑部病变治疗市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 静脉注射途径
• 玻璃体内注射途径

全球老龄化黄斑部病变治疗市场规模（按通路划分）及复合年增长率（2026-2033 年）

• 门诊手术中心
• 医院
• 其他分销管道

全球老龄化黄斑部病变治疗市场规模（按地区划分）及复合年增长率（2026-2033 年）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• F. Hoffmann-La Roche Ltd.（Switzerland）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Pfizer Inc.（United States）
• Regeneron Pharmaceuticals Inc.（United States）
• AbbVie Inc.（United States）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch Health Companies Inc.（Canada）
• Amgen Inc.（United States）
• Biogen Inc.（United States）
• Samsung Bioepis（South Korea）
• PanOptica（United States）
• REGENXBIO Inc.（United States）
• Lineage Cell Therapeutics（United States）
• Ocugen Inc.（United States）
• Olix Pharmaceuticals Inc.（South Korea）
• ONL Therapeutics（United States）
• MeiraGTx（United States）
• OnPoint Vision Inc.（United States）
• Alcon（Switzerland）

结论与建议

Global Macular Degeneration Treatment Market size was valued at USD 18.12 Billion in 2024 and is poised to grow from USD 19.66 Billion in 2025 to USD 37.76 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The global macular degeneration treatment market is experiencing rapid growth, driven by the increasing prevalence of age-related macular degeneration (AMD) and an aging population. This sector focuses on enhancing patient quality of life by addressing significant unmet medical needs. Key growth drivers include advancements in treatment technologies like anti-vascular endothelial growth factor (anti-VEGF) therapies and sustained-release drug delivery systems, which improve outcomes for patients. Additionally, heightened awareness of early detection boosts demand for effective therapies. However, obstacles such as high treatment costs and regulatory challenges persist. Noteworthy trends involve the rise of combination therapies that effectively target multiple disease pathways and emerging gene therapy approaches. Significant opportunities lie within untapped markets, particularly in regions like Asia-Pacific and Latin America, supported by advancements in AI and machine learning for personalized medicine.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macular Degeneration Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Macular Degeneration Treatment Market Segments Analysis

Global Macular Degeneration Treatment Market is segmented by Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel and region. Based on Type, the market is segmented into Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration and Others. Based on Treatment, the market is segmented into Anti-vascular Endothelial and Others. Based on Stage of Disease, the market is segmented into Early-stage AMD, Intermediate AMD and Late-stage AMD. Based on Route of Administration, the market is segmented into Intravenous Route and Intravitreal Route. Based on Distribution Channel, the market is segmented into Ambulatory Surgical Centres, Hospitals and Other Channels. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Macular Degeneration Treatment Market

The macular degeneration treatment market is significantly influenced by the growing aging population. As this condition predominantly impacts individuals over 50, the increasing number of older adults worldwide is anticipated to lead to a higher incidence of macular degeneration. With the global demographic trends indicating a substantial rise in the elderly population, the demand for effective treatments is expected to surge. This shift emphasizes the need for innovative therapeutic options to address the challenges posed by age-related macular degeneration, thereby driving market growth and encouraging advancements in treatment methodologies and healthcare solutions tailored to this demographic.

Restraints in the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market faces significant challenges due to stringent regulatory requirements and protracted approval processes for new therapies. The development of innovative treatment options necessitates extensive clinical trials, thorough safety assessments, and comprehensive regulatory submissions, all of which can be both time-consuming and financially burdensome. This complicated regulatory landscape may discourage some pharmaceutical companies from pursuing research and development in this area, ultimately restricting the introduction of novel treatments into the market. Consequently, the slow progression of new therapies can hinder patient access to advanced care options for macular degeneration.

Market Trends of the Global Macular Degeneration Treatment Market

The Global Macular Degeneration Treatment market is increasingly influenced by the rise of telemedicine and remote monitoring technologies, which have transformed patient care dynamics. This trend facilitates remote assessments of vision and disease progression, minimizing the necessity for frequent in-person appointments. By leveraging home-based visual acuity tests and smartphone imaging devices, healthcare providers can ensure timely interventions and better disease management, ultimately enhancing patient convenience and optimizing healthcare costs. This shift towards digital solutions is indicative of evolving healthcare practices, underscoring a commitment to improving patient outcomes while streamlining treatment protocols in the macular degeneration landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Macular Degeneration Treatment Market Size by Type & CAGR (2026-2033)

• Market Overview
• Dry Age-related Macular Degeneration
• Wet Age-related Macular Degeneration
• Others

Global Macular Degeneration Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Anti-vascular Endothelial
• Others

Global Macular Degeneration Treatment Market Size by Stage of Disease & CAGR (2026-2033)

• Market Overview
• Early-stage AMD
• Intermediate AMD
• Late-stage AMD

Global Macular Degeneration Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous Route
• Intravitreal Route

Global Macular Degeneration Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Ambulatory Surgical Centres
• Hospitals
• Other Channels

Global Macular Degeneration Treatment Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Stage of Disease, Route of Administration, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PanOptica (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lineage Cell Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocugen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olix Pharmaceuticals Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ONL Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OnPoint Vision Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations